{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:06:34Z","timestamp":1792782394039,"version":"4.5.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":518,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"name":"Mount Sinai School of Medicine, New York, NY","id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,4]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Hepatocellular carcinoma (HCC) is the most rapidly increasing cause of cancer-related mortality in the United States. Because of the lack of viable treatment options for HCC, prevention in high-risk patients has been proposed as an alternative strategy. The main risk factor for HCC is cirrhosis and several lines of evidence implicate epidermal growth factor (EGF) in the progression of cirrhosis and development of HCC. We therefore examined the effects of the EGF receptor (EGFR) inhibitor erlotinib on liver fibrogenesis and hepatocellular transformation in three different animal models of progressive cirrhosis: a rat model induced by repeated, low-dose injections of diethylnitrosamine (DEN), a mouse model induced by carbon tetrachloride (CCl\n                      <jats:sub>4<\/jats:sub>\n                      ), and a rat model induced by bile duct ligation (BDL). Erlotinib reduced EGFR phosphorylation in hepatic stellate cells (HSC) and reduced the total number of activated HSC. Erlotinib also decreased hepatocyte proliferation and liver injury. Consistent with all these findings, pharmacological inhibition of EGFR signaling effectively prevented the progression of cirrhosis and regressed fibrosis in some animals. Moreover, by alleviating the underlying liver disease, erlotinib blocked the development of HCC and its therapeutic efficacy could be monitored with a previously reported gene expression signature predictive of HCC risk in human cirrhosis patients.\n                      <jats:italic toggle=\"yes\">Conclusion<\/jats:italic>\n                      : These data suggest that EGFR inhibition using Food and Drug Administration-approved inhibitors provides a promising therapeutic approach for reduction of fibrogenesis and prevention of HCC in high-risk cirrhosis patients who can be identified and monitored by gene expression signatures. (HEPATOLOGY 2014;59:1577-1590)\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hep.26898","type":"journal-article","created":{"date-parts":[[2013,10,21]],"date-time":"2013-10-21T16:06:22Z","timestamp":1382371582000},"page":"1577-1590","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":328,"title":["Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma"],"prefix":"10.1097","volume":"59","author":[{"given":"Bryan C.","family":"Fuchs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujin","family":"Hoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y.","family":"Lauwers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"McGinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle K.","family":"DePeralta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xintong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lanuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony D.","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supriya","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Crenshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Onofrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Winckler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabeel","family":"Bardeesy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Caravan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd R.","family":"Golub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth K.","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-41-20250207","doi-asserted-by":"crossref","first-page":"6990","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics.","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"R2-41-20250207","first-page":"11181127","article-title":"Hepatocellular carcinoma.","volume":"365","author":"ElSerag","year":"2011","journal-title":"N Engl J Med"},{"key":"R3-41-20250207","doi-asserted-by":"crossref","first-page":"838851","DOI":"10.1016\/S0140-6736(08)60383-9","article-title":"Liver cirrhosis.","volume":"371","author":"Schuppan","year":"2008","journal-title":"Lancet"},{"key":"R4-41-20250207","doi-asserted-by":"crossref","first-page":"769775","DOI":"10.1002\/hep.25670","article-title":"Fibrosisdependent mechanisms of hepatocarcinogenesis.","volume":"56","author":"Zhang","year":"2012","journal-title":"Hepatology"},{"key":"R5-41-20250207","doi-asserted-by":"crossref","first-page":"821830","DOI":"10.1177\/002215540004800610","article-title":"Expression of epidermal growth factor and its receptor in cirrhotic liver disease.","volume":"48","author":"Komuves","year":"2000","journal-title":"J Histochem Cytochem"},{"key":"R6-41-20250207","doi-asserted-by":"crossref","first-page":"10241030","DOI":"10.1053\/j.gastro.2013.01.021","article-title":"Prognostic geneexpression signature for patients with hepatitis Crelated earlystage cirrhosis.","volume":"144","author":"Hoshida","year":"2013","journal-title":"Gastroenterology"},{"key":"R7-41-20250207","doi-asserted-by":"crossref","first-page":"19952004","DOI":"10.1056\/NEJMoa0804525","article-title":"Gene expression in fixed tissues and outcome in hepatocellular carcinoma.","volume":"359","author":"Hoshida","year":"2008","journal-title":"N Engl J Med"},{"key":"R8-41-20250207","doi-asserted-by":"crossref","first-page":"6873","DOI":"10.1016\/j.cyto.2011.10.018","article-title":"Association between the epidermal growth factor rs4444903 GG genotype and advanced fibrosis at a young age in chronic hepatitis C.","volume":"57","author":"Falleti","year":"2012","journal-title":"Cytokine"},{"key":"R9-41-20250207","doi-asserted-by":"crossref","first-page":"296302","DOI":"10.1111\/j.1365-2249.2011.04497.x","article-title":"Carriage of the EGF rs4444903 AG functional polymorphism associates with disease progression in chronic HBV infection.","volume":"167","author":"Cmet","year":"2012","journal-title":"Clin Exp Immunol"},{"key":"R10-41-20250207","doi-asserted-by":"crossref","first-page":"5360","DOI":"10.1001\/jama.2007.65","article-title":"Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis.","volume":"299","author":"Tanabe","year":"2008","journal-title":"JAMA"},{"key":"R11-41-20250207","first-page":"765768","article-title":"Autocrine mitogen IgEGF cooperates with cmyc or with the Hcs locus during hepatocarcinogenesis in transgenic mice.","volume":"10","author":"Tonjes","year":"1995","journal-title":"Oncogene"},{"key":"R12-41-20250207","first-page":"7080","article-title":"Expression of ErbB receptor proteins and TGFalpha during diethylnitrosamineinduced hepatocarcinogenesis in the rat liver.","volume":"13","author":"Lee","year":"2007","journal-title":"Korean J Hepatol"},{"key":"R13-41-20250207","doi-asserted-by":"crossref","first-page":"307314","DOI":"10.1002\/hep.20538","article-title":"Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis.","volume":"41","author":"Schiffer","year":"2005","journal-title":"Hepatology"},{"key":"R14-41-20250207","first-page":"690713","article-title":"Chronic hepatitis: morphology and nomenclature.","volume":"7","author":"Ishak","year":"1994","journal-title":"Mod Pathol"},{"key":"R15-41-20250207","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1471-230X-10-79","article-title":"Mouse model of carbon tetrachloride induced liver fibrosis: histopathological changes and expression of CD133 and epidermal growth factor.","volume":"10","author":"Fujii","year":"2010","journal-title":"BMC Gastroenterol"},{"key":"R16-41-20250207","first-page":"11291159","article-title":"Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges.","volume":"12","author":"Hoshida","year":"2012","journal-title":"Curr Cancer Drug Targets"},{"key":"R17-41-20250207","doi-asserted-by":"crossref","first-page":"1114111146","DOI":"10.1158\/0008-5472.CAN-07-1369","article-title":"Role of CYP2E1 in diethylnitrosamineinduced hepatocarcinogenesis in vivo.","volume":"67","author":"Kang","year":"2007","journal-title":"Cancer Res"},{"key":"R18-41-20250207","doi-asserted-by":"crossref","first-page":"109118","DOI":"10.1006\/taap.1998.8547","article-title":"Resistance to carbon tetrachlorideinduced hepatotoxicity in mice which lack CYP2E1 expression.","volume":"153","author":"Wong","year":"1998","journal-title":"Toxicol Appl Pharmacol"},{"key":"R19-41-20250207","doi-asserted-by":"crossref","first-page":"35073512","DOI":"10.1073\/pnas.1222878110","article-title":"Genomic responses in mouse models poorly mimic human inflammatory diseases.","volume":"110","author":"Seok","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R20-41-20250207","first-page":"317324","article-title":"Sequential assessment of the intrahepatic expression of epidermal growth factor and transforming growth factorbeta1 in hepatofibrogenesis of a rat cirrhosis model.","volume":"19","author":"Kuriyama","year":"2007","journal-title":"Int J Mol Med"},{"key":"R21-41-20250207","doi-asserted-by":"crossref","first-page":"683696","DOI":"10.1016\/j.yexcr.2008.07.029","article-title":"Endocytosis and intracellular trafficking of ErbBs.","volume":"315","author":"Sorkin","year":"2009","journal-title":"Exp Cell Res"},{"key":"R22-41-20250207","doi-asserted-by":"crossref","first-page":"713725","DOI":"10.3181\/0901-MR-12","article-title":"The epidermal growth factor receptor: a link between inflammation and liver cancer.","volume":"234","author":"Berasain","year":"2009","journal-title":"Exp Biol Med"},{"key":"R23-41-20250207","doi-asserted-by":"crossref","first-page":"1708117086","DOI":"10.1073\/pnas.0704126104","article-title":"The EGF receptor is required for efficient liver regeneration.","volume":"104","author":"Natarajan","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R24-41-20250207","doi-asserted-by":"crossref","first-page":"16551669","DOI":"10.1053\/j.gastro.2008.03.003","article-title":"Mechanisms of hepatic fibrogenesis.","volume":"134","author":"Friedman","year":"2008","journal-title":"Gastroenterology"},{"key":"R25-41-20250207","doi-asserted-by":"crossref","first-page":"125172","DOI":"10.1152\/physrev.00013.2007","article-title":"Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver.","volume":"88","author":"Friedman","year":"2008","journal-title":"Physiol Rev"},{"key":"R26-41-20250207","doi-asserted-by":"crossref","first-page":"147159","DOI":"10.1053\/gast.2003.50012","article-title":"Liver fibrosis: insights into migration of hepatic stellate cells in response to extracellular matrix and growth factors.","volume":"124","author":"Yang","year":"2003","journal-title":"Gastroenterology"},{"key":"R27-41-20250207","doi-asserted-by":"crossref","first-page":"2217322183","DOI":"10.1074\/jbc.M109.005355","article-title":"Bile acidinduced epidermal growth factor receptor activation in quiescent rat hepatic stellate cells can trigger both proliferation and apoptosis.","volume":"284","author":"Sommerfeld","year":"2009","journal-title":"J Biol Chem"},{"key":"R28-41-20250207","doi-asserted-by":"crossref","first-page":"13241332","DOI":"10.1038\/nm1663","article-title":"TLR4 enhances TGFbeta signaling and hepatic fibrosis.","volume":"13","author":"Seki","year":"2007","journal-title":"Nat Med"},{"key":"R29-41-20250207","doi-asserted-by":"crossref","first-page":"589595","DOI":"10.1038\/nm.2341","article-title":"EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.","volume":"17","author":"Lupberger","year":"2011","journal-title":"Nat Med"},{"key":"R30-41-20250207","doi-asserted-by":"crossref","first-page":"12511261","DOI":"10.1002\/hep.22437","article-title":"The epidermal growth factor receptor ligand amphiregulin participates in the development of mouse liver fibrosis.","volume":"48","author":"Perugorria","year":"2008","journal-title":"Hepatology"},{"key":"R31-41-20250207","doi-asserted-by":"crossref","first-page":"703712","DOI":"10.1038\/labinvest.2012.3","article-title":"Heparinbinding epidermal growth factorlike growth factor suppresses experimental liver fibrosis in mice.","volume":"92","author":"Huang","year":"2012","journal-title":"Lab Invest"},{"key":"R32-41-20250207","first-page":"108115","article-title":"Epidermal growth factor receptor and HER3 restrict cell response to sorafenib in hepatocellular carcinoma cells.","volume":"57","author":"BlivetVan Eggelpoel","year":"2012","journal-title":"J Hepatol"},{"key":"R33-41-20250207","doi-asserted-by":"crossref","first-page":"66576663","DOI":"10.1200\/JCO.2005.14.696","article-title":"Phase II study of Erlotinib (OSI774) in patients with advanced hepatocellular cancer.","volume":"23","author":"Philip","year":"2005","journal-title":"J Clin Oncol"},{"key":"R34-41-20250207","doi-asserted-by":"crossref","first-page":"10591067","DOI":"10.1002\/cncr.22886","article-title":"Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma.","volume":"110","author":"Thomas","year":"2007","journal-title":"Cancer"},{"key":"R35-41-20250207","doi-asserted-by":"crossref","first-page":"12941306","DOI":"10.1002\/hep.23123","article-title":"Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies.","volume":"50","author":"Popov","year":"2009","journal-title":"Hepatology"},{"key":"R36-41-20250207","doi-asserted-by":"crossref","first-page":"19071917","DOI":"10.1016\/S0140-6736(03)14964-1","article-title":"Hepatocellular carcinoma.","volume":"362","author":"Llovet","year":"2003","journal-title":"Lancet"},{"key":"R37-41-20250207","doi-asserted-by":"crossref","first-page":"138148","DOI":"10.1053\/j.gastro.2008.09.014","article-title":"Incidence of hepatocellular carcinoma and associated risk factors in hepatitis Crelated advanced liver disease.","volume":"136","author":"Lok","year":"2009","journal-title":"Gastroenterology"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.26898","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201404000-00041","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T12:00:20Z","timestamp":1738929620000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201404000-00041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.26898","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]}}}